A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Exclusion Criteria

• •1. Presence of known inhibitors to FVII or FVIIa
• •2. History of clinically significant hypersensitivity associated with monoclonal antibody therapies.
• •3. History of venous or arterial thrombosis or thromboembolic disease, with the exception of catheter-associated superficial vein thrombosis.
• •4. Known thrombophilia risk by the following criteria: Homozygous Factor V Leiden (FVL), compound heterozygous FVL/Prothrombin gene mutation, antithrombin \<50%, congenital protein C, and protein S deficiency with levels \<50%.
• •5. Clinically significant comorbidity that may interfere with study participation.
• •6. Use of concomitant therapy not permitted during the study (i.e., other platelet inhibitors, desmopressin, fibrinolysis inhibitors, except if used as local treatment \[e.g., for oral bleeds\])
• •7. Female participants who are pregnant or breastfeeding.